| Virksomhedsstatus | | NORMAL. |
| Sidst opdateret den 05.07.2016 og
angivet som gældende fra 04.07.2016 (2973
dage). |
Ingen historik.
| Branche | | Forskning og eksperimentel udvikling indenfor bioteknologi (721100). |
| Sidst opdateret den 05.07.2016 og
angivet som gældende fra 04.07.2016 (2973
dage). |
Ingen historik.
| Revisionfravalgt | | false. |
| Sidst opdateret den 30.10.2017 og
angivet som gældende fra 26.10.2017 (2494
dage). |
| Historik | Start | Stop |
|---|
| false | 26.10.2017 | |
| true | 04.07.2016 | 25.10.2017 |
| Kontaktoplysninger | | akr@resotherpharma.com. |
| Sidst opdateret den 27.02.2023 og
angivet som gældende fra 27.02.2023 (544
dage). |
| Historik | Start | Stop |
|---|
| akr@resotherpharma.com | 27.02.2023 | |
| lone.veng@resotherpharma.com | 21.08.2017 | 26.02.2023 |
| tenj@txppharma.com | 04.07.2016 | 20.08.2017 |
Ingen nuværende registrering.
Ingen historik.
| Navne | | ResoTher Pharma A/S. |
| Sidst opdateret den 30.05.2022 og
angivet som gældende fra 18.05.2022 (829
dage). |
| Historik | Start | Stop |
|---|
| ResoTher Pharma A/S | 18.05.2022 | |
| ResoTher Pharma ApS | 04.07.2016 | 17.05.2022 |
| Tegningsregel | | Selskabet tegnes af en direktør og et bestyrelsesmedlem i forening, eller af den samlede bestyrelse. |
| Sidst opdateret den 27.06.2024 og
angivet som gældende fra 27.06.2024 (58
dage). |
| Fortolkning
(2 tegningsmuligheder)
| | 1 direktør + 1 bestyrelsesmedlem |
| bestyrelsen |
| Historik | Start | Stop |
|---|
| Selskabet tegnes af en direktør og et bestyrelsesmedlem i forening, eller af den samlede bestyrelse | 27.06.2024 | |
| Selskabet tegnes af den samlede bestyrelse eller af et bestyrelsesmedlem og en direktør i forening | 04.07.2016 | 26.06.2024 |
Type af revisorbistand:Auditor's report on audited financial statements
Navn på revisionsvirksomhed:EY Godkendt Revisionspartnerselskab
Revisionsvirksomhedens CVR-nr.:30700228
Beskrivelse af revisor:State Authorised Public Accountant
Virksomhedens regnskabsklasse:Reporting class B
Grundlag for konklusion (revision):Basis for Opinion We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. Independence We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code.
Konklusion (revision):Opinion We have audited the financial statements of ResoTher Pharma A/S for the financial year January 1 – December 31, 2023, which comprise income statement and statement of comprehensive income, balance sheet, cash flow statement, and statement of changes in equity and notes, including material accounting policy information. The financial statements are prepared in accordance with IFRS Accounting Standards as adopted by the EU and additional requirements of the Danish Financial Statements Act. In our opinion, the financial statements give a true and fair view of the financial position of the Company at December 31, 2023 and of the results of the Company's operations and cash flows for the financial year January 1 – December 31, 2023 in accordance with IFRS Accounting Standards as adopted by the EU and additional requirements of the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Statement on the Management’s review Management is responsible for the Management's review. Our opinion on the financial statements døs not cover the Management's review, and we do not express any assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements, or our knowledge obtained during the audit, or otherwise appears to be materially misstated. Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act. Based on our procedures, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of the Management's review.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
LoginOpret gratis brugere-conomic integration